NEW YORK — Wall Street opened the fourth quarter with bond yields near multi-decade highs and investors worried that artificial intelligence could disrupt entire industries — but some of Thursday’s biggest stock moves told a very different story.
Accenture surged after proving companies are still willing to spend heavily on consultants to deploy AI.
Synopsys jumped after unveiling ambitious long-term growth targets and major agreements with:
OpenAI
and
Amazon Web Services.
Vicor rallied after raising its revenue outlook again as royalties tied to AI power-delivery technology came in stronger than expected.
United Therapeutics extended gains after winning a major patent battle that could severely restrict one of its biggest emerging competitors.
Meanwhile, Sigma Lithium sank after suspending production amid a Brazilian legal dispute.
And Corteva appeared to collapse by more than:
80%.
But that last move came with an important caveat:
the apparent plunge followed the separation of its Vylor seed and genetics business and therefore included a major mechanical adjustment associated with the spinoff.
The result was a trading session where the broad indexes barely moved — but underneath the surface, individual stocks experienced enormous repricing.
ACCENTURE BECAME THE DAY’S BIGGEST AI SURPRISE
Accenture was one of Thursday’s standout winners.
The consulting giant initially traded about:
18% higher
during the session.
Reuters later reported shares rising as much as:
22%,
putting the stock on track for its:
best trading day ever.
The catalyst was stronger-than-expected fiscal fourth-quarter results and a fiscal 2027 outlook that challenged one of Wall Street’s most persistent AI fears:
What if artificial intelligence destroys the consulting industry?
Accenture’s results suggested the answer may be much more complicated.
ACCENTURE REVENUE HIT $18.68 BILLION
The company reported quarterly revenue of:
$18.68 billion.
That exceeded:
Accenture’s own guidance of $17.8 billion to $18.4 billion
and Wall Street expectations around:
$18.0 billion to $18.3 billion.
Adjusted earnings came in at:
$3.29 per share.
Bookings also remained strong.
Fourth-quarter bookings increased:
4%
to:
$22.17 billion.
Consulting revenue rose:
7%
to approximately:
$9.28 billion.
Those numbers mattered because investors had spent months worrying that AI agents could automate much of the work traditionally performed by consultants.
INSTEAD OF DESTROYING CONSULTING, AI MAY BE CREATING MORE WORK
The emerging counterargument is straightforward.
Companies may buy powerful AI models.
But they still need help figuring out:
Which systems to use
How to connect them to existing software
How to protect sensitive data
How to redesign workflows
and
How to measure whether AI actually saves money.
That creates enormous implementation work.
Companies such as Accenture increasingly position themselves as the bridge between:
AI technology
and
Real-world corporate operations.
That is why strong AI adoption could create consulting demand even while automating some traditional tasks.
ACCENTURE EXPECTS 3% TO 6% REVENUE GROWTH
For fiscal 2027, Accenture expects revenue growth of approximately:
3% to 6%.
The midpoint is above analysts’ prior average expectation of roughly:
3.9%.
That was enough to force investors to reconsider an extremely bearish narrative around the industry.
Before Thursday, Accenture shares had fallen roughly:
one-third during 2026.
Investors had effectively priced in serious AI disruption.
The earnings report suggested that disruption may instead become a new revenue stream.
OTHER CONSULTING STOCKS RALLIED TOO
Accenture’s results lifted the entire industry.
Cognizant rose approximately:
8%.
IBM gained around:
3%.
U.S.-listed shares of Infosys and Wipro climbed roughly:
6% to 7%.
That shows Thursday’s move was not viewed as an Accenture-only event.
Investors were reassessing whether IT services companies could become:
AI beneficiaries
rather than
AI casualties.
BUT AI IS STILL PRESSURING ACCENTURE’S PRICING
The story is not completely bullish.
Accenture said pricing was lower in many areas during the quarter.
Why?
Because customers increasingly expect consultants to share some of the efficiency gains created by AI.
If an AI agent allows a project to be completed with fewer workers or fewer hours, customers want lower prices.
That means AI can simultaneously:
Increase demand
and
Reduce pricing power.
The long-term winner will likely be the company that automates work faster than prices decline.
ACCENTURE IS PREPARING ANOTHER $5 BILLION ACQUISITION PUSH
CEO Julie Sweet said Accenture expects to deploy approximately:
$5 billion
toward acquisitions during fiscal 2027.
The goal is to accelerate growth in areas including:
Artificial intelligence
Cybersecurity
Cloud infrastructure
and
Specialized digital services.
The company had already announced roughly:
$4.18 billion
of cybersecurity transactions in June.
That includes a majority investment in industrial cybersecurity specialist:
Dragos.
The strategy suggests Accenture intends to buy capabilities quickly rather than build everything internally.
ACCENTURE IS ALSO SPENDING HEAVILY ON AI SAFETY
Another unusual development is the company’s partnership with:
Anthropic.
Accenture and Anthropic committed at least:
$1 billion each
over five years toward AI testing and safety capabilities.
That partnership gives Accenture another possible source of differentiation.
Large corporations increasingly need someone to evaluate whether powerful AI systems are:
Reliable
Secure
Compliant
and
Appropriate for enterprise deployment.
That could become a major consulting category in its own right.
SYNOPSYS SURGED AFTER ITS INVESTOR DAY
Synopsys was another major winner.
Shares climbed more than:
8% at midday
and Reuters later reported a gain around:
10%.
The semiconductor-design software company delivered several catalysts at once.
It issued fiscal 2027 forecasts above analysts’ expectations.
It outlined aggressive long-term growth goals.
It announced a major AI partnership with:
OpenAI.
And Amazon Web Services agreed to a large licensing deal.
For a company already positioned at the center of semiconductor design, that was enough to trigger a powerful rally.
SYNOPSYS EXPECTS MORE THAN $11 BILLION IN 2027 REVENUE
For the fiscal year ending October 31, 2027, Synopsys forecast revenue between:
$11.10 billion
and
$11.20 billion.
Wall Street had expected approximately:
$10.81 billion.
Synopsys also forecast earnings per share between:
$19.04
and
$19.12.
Analysts had expected roughly:
$17.81.
That is a substantial earnings beat embedded in forward guidance.
SYNOPSYS ALSO TARGETS 15% LONG-TERM GROWTH
Management laid out an even more ambitious longer-term plan.
Synopsys is targeting approximately:
15% compound annual revenue growth
from fiscal 2026 through:
2030.
It also wants adjusted operating margins around:
50%
by 2030.
That is significant because chip-design software already enjoys attractive economics.
If AI-driven semiconductor complexity increases demand while Synopsys expands margins, profits could grow considerably faster than revenue.
OPENAI IS NOW HELPING BUILD AI FOR CHIP DESIGN
One of the biggest announcements involved:
OpenAI.
Synopsys and OpenAI agreed to develop an AI model specifically designed to work with semiconductor-design tools.
The idea is to teach AI how engineers make trade-offs involving:
Chip performance
Power consumption
Physical layout
Timing
and
Manufacturing constraints.
Chip design can involve millions or billions of interconnected decisions.
AI could automate some of that work.
Instead of replacing Synopsys, OpenAI may therefore make Synopsys software more valuable.
AWS SIGNED A DEAL WORTH MORE THAN $1 BILLION
Amazon Web Services also signed a multiyear agreement worth more than:
$1 billion
to license Synopsys intellectual property.
That provides another strong validation point.
Hyperscalers increasingly design their own silicon.
Amazon has:
Trainium
Inferentia
and other custom chips.
Google has TPUs.
Microsoft has Maia.
Meta has MTIA.
Every custom semiconductor program creates demand for sophisticated chip-design tools.
That benefits Synopsys.
AI MAY ACTUALLY MAKE CHIP DESIGN HARDER
Artificial intelligence is often associated with automation and simplicity.
But AI chips themselves are becoming more complex.
Modern accelerators combine:
Compute dies
High-bandwidth memory
Advanced packaging
Networking
and
Power-management systems.
Engineers need software to simulate and verify increasingly complicated designs.
That expands Synopsys’ opportunity.
The company is effectively selling picks and shovels to the AI semiconductor gold rush.
SYNOPSYS ALSO PLANS A $1 BILLION BUYBACK
Management said the company intends to repurchase approximately:
$1 billion of shares
over the coming months.
That adds another source of support for shareholders.
More importantly, it suggests management believes it can simultaneously:
Invest heavily in growth
and
Return capital.
Wall Street responded accordingly.
UNITED THERAPEUTICS EXTENDED ITS PATENT-VICTORY RALLY
United Therapeutics was one of the biggest healthcare movers.
Shares gained roughly:
6% during Thursday’s session
after already jumping more than:
12% the previous day.
The catalyst was a major court victory against:
Liquidia.
A Delaware federal court ruled that Liquidia’s drug:
Yutrepia
infringed two valid claims of a United Therapeutics patent.
That ruling significantly changes the competitive outlook for one of United Therapeutics’ most important businesses.
THE CASE CENTERS ON A RARE LUNG DISEASE
The dispute involves treatments for:
pulmonary hypertension associated with interstitial lung disease, or PH-ILD.
United Therapeutics markets inhaled treprostinil under its:
Tyvaso
franchise.
Liquidia developed:
Yutrepia,
a dry-powder formulation of the same underlying active ingredient.
Investors viewed Yutrepia as a potentially significant competitor.
The court ruling could substantially restrict that threat.
THE COURT FOUND TWO PATENT CLAIMS VALID AND INFRINGED
The U.S. District Court for the District of Delaware concluded that Liquidia infringed claims:
1
and
14
of United Therapeutics’ U.S. Patent No.:
11,826,327.
The court also rejected Liquidia’s argument that those claims were invalid.
That matters enormously.
A patent is only useful if it survives legal challenge.
The decision strengthened United Therapeutics’ intellectual-property protection around the PH-ILD indication.
UNITED THERAPEUTICS MAY SEEK YUTREPIA’S REMOVAL FOR PH-ILD
United Therapeutics says it believes the ruling entitles it to seek an order requiring the FDA to withdraw approval of Yutrepia for the affected indication.
If that happens, Yutrepia could be removed from the PH-ILD market until labeling is revised.
United Therapeutics also intends to pursue:
monetary damages
for past infringement.
Those damages could potentially include royalties on Yutrepia sales.
A final judgment is expected after additional court proceedings.
LIQUIDIA PLANS TO APPEAL
The case is not necessarily finished.
Liquidia CEO Roger Jeffs said the company disagrees with the ruling and intends to pursue:
available appellate options.
Liquidia has also indicated it may ask the FDA to remove the PH-ILD indication from Yutrepia’s label.
So Thursday’s stock reaction reflects investors’ interpretation of the current legal position.
It does not mean every legal issue has been permanently resolved.
LIQUIDIA LOST BILLIONS IN MARKET VALUE
Liquidia shares had plunged roughly:
50% to 57%
when the ruling was announced.
Reuters estimated the company was on track to lose approximately:
$3.18 billion
of market capitalization if those losses held.
Shares fell again Thursday.
That is an extraordinary example of how a single patent decision can redistribute billions of dollars of expected future value between two pharmaceutical companies.
BTIG UPGRADED UNITED THERAPEUTICS
After the ruling, BTIG upgraded United Therapeutics to:
Buy.
The brokerage argued that the legal victory could clear a path toward renewed growth through:
2027.
BTIG simultaneously downgraded Liquidia to:
Neutral.
Other analysts also described the decision as significantly improving United Therapeutics’ competitive position.
Again, those ratings are analyst assessments rather than guarantees of future performance.
VICOR SURGED AFTER RAISING GUIDANCE — AGAIN
Another striking move came from:
Vicor.
The power-electronics company jumped roughly:
10% to 12%.
The reason was simple:
Vicor raised its third-quarter revenue growth guidance for the second time in a short period.
The company now expects sequential revenue growth of:
more than 30%.
Previously it had expected:
at least 20%.
And only shortly before that, guidance had been closer to:
10%.
That is an unusually rapid series of upward revisions.
THE SURPRISE CAME FROM ROYALTY REVENUE
Vicor attributed the stronger outlook to higher-than-expected royalties from a customer licensing its:
Vertical Power Delivery
technology.
That technology is particularly relevant to:
AI processors
and
high-performance computing.
As AI chips consume more electricity, supplying power efficiently becomes increasingly difficult.
The power system itself is becoming a critical engineering constraint.
That is where Vicor sees its opportunity.
AI CHIPS NEED FAR MORE THAN SEMICONDUCTORS
A modern AI accelerator may consume:
hundreds
or even more than:
1,000 watts
depending on system design.
Entire racks can consume enormous amounts of electricity.
Delivering that power efficiently matters because lost electricity becomes:
heat.
More heat requires more cooling.
More cooling requires more electricity.
That means better power conversion can directly improve data-center economics.
Vicor’s technology is designed to move power closer to processors while reducing losses.
VICOR IS TURNING INTELLECTUAL PROPERTY INTO ROYALTIES
The most interesting part of the story may be the business model.
Instead of manufacturing every component itself, Vicor can license its technology.
That allows customers or suppliers to use Vicor’s intellectual property while paying:
royalties.
Royalty revenue can be extremely attractive because it requires less manufacturing capital than selling physical products.
If AI infrastructure demand continues growing, licensing could become a much larger part of Vicor’s economics.
VICOR HAS SIGNED MULTIPLE LICENSING AGREEMENTS
CEO Patrizio Vinciarelli has said the company secured licensing agreements with several major firms, including hyperscalers and original-equipment manufacturers.
Some customers reportedly chose licensing after intellectual-property disputes involving unlicensed power components.
That creates an unusual competitive advantage.
Vicor is not only selling technology.
It is also monetizing patents protecting that technology.
That combination helped drive the stock’s extraordinary rally.
VICOR HAS ALREADY RISEN DRAMATICALLY
Before Thursday’s move, Vicor had already been one of the strongest-performing technology stocks of 2026.
Barron’s reported the shares were up roughly:
194% year to date
and about:
560% over the preceding 12 months
around the time of the latest rally.
Those gains make valuation and expectations increasingly important.
A business can perform extremely well and still disappoint investors if the stock price already assumes extraordinary growth.
That remains a major risk.
CONSTELLATION ENERGY CLIMBED ON A 20-YEAR AMAZON DEAL
Constellation Energy gained roughly:
3%.
The nuclear-power operator announced a long-term agreement with:
Amazon.
The deal is intended to support expansion of generating capacity at a nuclear facility in:
Maryland.
That fits one of Wall Street’s strongest themes:
AI data centers need enormous amounts of electricity.
Technology companies increasingly want long-duration power contracts to guarantee supply.
Nuclear energy has become particularly attractive because it can provide:
24-hour electricity
with relatively low direct carbon emissions.
AI IS TURNING POWER COMPANIES INTO TECHNOLOGY PLAYS
For decades, utilities and power producers were considered relatively slow-growth investments.
Artificial intelligence is changing that perception.
Data centers require massive amounts of power.
That is increasing demand for:
Nuclear plants
Natural gas
Grid infrastructure
Transformers
and
Power-management equipment.
Constellation Energy and Vicor therefore represent two different layers of the same AI infrastructure story.
One produces electricity.
The other helps deliver it efficiently to advanced processors.
SIGMA LITHIUM PLUNGED AFTER SUSPENDING PRODUCTION
Not every big move was positive.
Sigma Lithium shares sank approximately:
16%.
The Brazilian lithium producer temporarily suspended:
mining
and
industrial production.
The company cited delays involving a legal proceeding connected with litigation filed by a:
nongovernmental organization.
That introduced immediate uncertainty around production and shipments.
For commodity producers, even temporary stoppages can have significant financial consequences.
LITHIUM HAS ALREADY BEEN A DIFFICULT MARKET
The suspension arrives at a challenging time for the lithium industry.
Lithium prices have experienced extreme volatility after enormous investment in:
EV batteries
and
mining capacity.
Producers must manage:
Commodity prices
Operating costs
Environmental approvals
and
Local permitting.
A legal interruption adds another layer of risk.
That explains why investors reacted sharply.
ACUITY FELL DESPITE ITS SMART-BUILDING EXPOSURE
Acuity shares declined roughly:
4%.
The company makes products including:
Lighting systems
and
Building-management technology.
Its Acuity Intelligent Spaces business has exposure to growing demand for smarter commercial infrastructure.
But forward guidance called for:
low- to mid-teens sales growth
in that segment.
StreetAccount indicated that was slightly below Wall Street expectations.
That illustrates a recurring feature of today’s market:
good growth is not enough when investors expect exceptional growth.
BJ’S RESTAURANTS JUMPED AFTER AN ANALYST UPGRADE
BJ’s Restaurants gained approximately:
5%.
Mizuho upgraded the restaurant chain to:
Outperform
and raised its price target to:
$76.
The bank increased its estimate for third-quarter same-store sales growth to:
5.5%.
Previously it expected:
4.6%.
Consensus was closer to:
4.3%.
Mizuho said its channel checks pointed toward stronger business momentum.
Restaurants are highly sensitive to consumer spending, so improving same-store sales can significantly change earnings expectations.
MCKESSON ROSE AFTER REAFFIRMING ITS OUTLOOK
McKesson shares gained around:
4%.
The healthcare distribution giant reaffirmed its fiscal 2027 earnings-per-share guidance.
It also extended its relationship with:
CVS Health
through:
June 2032.
McKesson will continue distributing pharmaceuticals to CVS:
Retail pharmacies
Mail-order operations
Specialty pharmacies
and
Distribution facilities.
Long-term customer agreements provide investors with greater revenue visibility.
MCCORMICK FELL EVEN AFTER BEATING EXPECTATIONS
McCormick offered another example of how difficult earnings reactions can be.
The spice maker beat Wall Street expectations.
Adjusted earnings were:
86 cents per share
versus approximately:
76 cents expected.
Revenue reached:
$2.02 billion
versus about:
$1.98 billion expected.
Yet the stock fell more than:
2%.
That reminds investors that stock moves are based not only on whether companies beat published estimates.
They also depend on:
Guidance
Valuation
Whisper expectations
and
Management commentary.
CORTEVA’S 84% “CRASH” NEEDS IMPORTANT CONTEXT
Corteva appeared to be the day’s most shocking loser.
CNBC’s midday list showed the remaining Corteva shares down approximately:
84%.
But investors should not interpret that figure like a normal stock collapse.
Corteva completed the separation of:
Vylor
its seed and genetics operation.
Following the transaction, the remaining Corteva business became a more focused:
crop-protection company.
When a company spins off a major business, value is transferred into the newly separated stock.
The parent share price can therefore drop mechanically.
A SPINOFF CHANGES WHERE SHAREHOLDER VALUE SITS
Consider a simplified example.
Suppose a company worth:
$100
splits into:
Company A worth $20
and
Company B worth $80.
Company A’s stock could appear to fall:
80%.
But shareholders may now own both securities.
Their economic loss is not automatically 80%.
That is why raw percentage moves around corporate separations can be misleading.
Investors need to compare the value of:
both post-spinoff holdings
with the original investment.
CALIFORNIA HAD TRIED TO DELAY THE SEPARATION
The Vylor transaction also faced a legal challenge.
An appeals court denied California’s attempt to secure a temporary restraining order and preliminary injunction that would have delayed the spinoff.
That allowed the separation to proceed.
The legal dispute added complexity to an already confusing trading move.
It is exactly the kind of situation where headline percentage declines should be interpreted cautiously.
THE BROADER MARKET BARELY MOVED
What makes Thursday particularly interesting is that all these dramatic stock movements occurred while major indexes finished almost unchanged.
The:
Dow Jones Industrial Average rose 0.04%.
The:
S&P 500 gained 0.20%.
The:
Nasdaq Composite added 0.04%.
That means the day’s biggest opportunities and risks were happening far beneath the index level.
TREASURY YIELDS WERE THE BIG OVERHANG
The 10-year Treasury yield initially surged toward:
5.34%.
That was around its highest level since:
2002.
Higher bond yields create pressure on stocks because investors can earn attractive returns from relatively low-risk government securities.
They also raise:
Mortgage costs
Corporate borrowing costs
and
Discount rates used to value future earnings.
Growth companies are particularly sensitive.
FED COMMENTS HELPED YIELDS RETREAT
Treasury yields later moved lower.
Federal Reserve officials indicated policymakers could remain patient before raising rates again.
That helped stabilize equities.
By the close, the 10-year yield had retreated from its session high.
The reversal allowed the stock market to finish slightly positive.
But the broader environment remained challenging.
THIS IS WHY COMPANY-SPECIFIC CATALYSTS MATTER SO MUCH
When the entire market is rising rapidly, mediocre companies can sometimes rally simply because money is flowing into equities.
When:
Treasury yields exceed 5%
and
market indexes are struggling,
investors become much more selective.
Stocks need clear catalysts.
On Thursday, the strongest catalysts included:
Accenture — earnings and AI demand
Synopsys — AI partnerships and strong guidance
United Therapeutics — patent protection
Vicor — royalty-driven guidance increase
and
Constellation Energy — long-term AI power demand.
That is why those stocks could rally even while the overall market barely moved.
AI CONNECTED SEVERAL OF THE DAY’S BIGGEST WINNERS
The strongest common theme was artificial intelligence.
Accenture is helping businesses implement AI.
Synopsys is helping companies design AI chips.
Vicor is supplying power technology for AI processors.
Constellation Energy is supplying electricity needed for data centers.
These companies operate in completely different industries.
Yet each occupies a different layer of the same AI investment cycle.
That shows how far the AI boom has spread beyond semiconductor manufacturers.
THE AI TRADE IS BECOMING A SUPPLY-CHAIN TRADE
Early in the AI rally, investors concentrated heavily on companies such as:
Nvidia
AMD
and
Broadcom.
The next phase is broader.
Building an AI data center requires:
Chip-design software
Consultants
Electricity
Cooling
Networking
Power conversion
Transformers
Construction
and
Cybersecurity.
That creates second-order beneficiaries.
Thursday’s market movers offered a clear example.
ACCENTURE MAY BE THE MOST IMPORTANT SIGNAL
Of all the moves, Accenture’s may have the broadest implications.
Earlier in 2026, investors became convinced that AI agents could destroy enormous parts of the software and consulting industries.
The logic was compelling.
If AI performs more:
Coding
Analysis
Customer support
and
Administrative work,
companies need fewer human consultants.
But Accenture’s results suggest another possibility.
AI may automate some work while simultaneously creating a huge need for experts who can implement it.
That distinction could determine which professional-services stocks survive the AI transition.
SYNOPSYS SHOWS SOFTWARE CAN BECOME MORE IMPORTANT TOO
Synopsys offers a similar lesson.
AI could theoretically automate chip design.
That sounds threatening for traditional electronic-design software.
But if AI enables engineers to build:
more complicated chips
faster
and
in larger numbers,
demand for the underlying design platform may increase.
OpenAI’s partnership with Synopsys suggests the AI model may operate:
inside the existing software ecosystem
rather than replace it.
That is an important distinction for the entire software sector.
VICOR SHOWS INTELLECTUAL PROPERTY CAN SCALE FASTER THAN FACTORIES
Vicor demonstrates another AI business model.
Instead of trying to manufacture every component required by the data-center boom, it can license technology and collect:
royalties.
If customers adopt that technology at scale, revenue can grow without equivalent growth in factory investment.
That is why investors reacted so strongly to the royalty surprise.
The key question now is whether those payments are:
repeatable
and
scalable.
UNITED THERAPEUTICS SHOWS HOW DIFFERENT BIOTECH IS
United Therapeutics had nothing to do with AI.
Its rally came from something completely different:
intellectual-property protection.
For pharmaceutical companies, patents can determine billions of dollars in future revenue.
A single court decision can protect:
market exclusivity
or
destroy a competitor’s commercial strategy.
That is exactly what investors believe may have happened in the United-Liquidia dispute.
THE BIGGER STORY: WALL STREET’S INDEXES LOOKED QUIET — BUT BILLIONS OF DOLLARS WERE BEING REPRICED UNDERNEATH
October 1 looked relatively calm if investors watched only the:
Dow
S&P 500
and
Nasdaq.
All three finished close to flat.
But underneath those averages, extraordinary changes were taking place.
Accenture experienced what Reuters described as a potential:
best-ever trading day.
Synopsys gained roughly:
10%
as AI pushed chip-design expectations higher.
Vicor surged after raising guidance for the second time as AI-related royalties exceeded expectations.
United Therapeutics added billions in market value after securing stronger patent protection.
Liquidia lost a huge portion of its valuation.
Sigma Lithium plunged after stopping production.
And Corteva’s apparent collapse demonstrated why corporate actions can make percentage stock moves deeply misleading.
The lesson is bigger than any one ticker.
Wall Street is becoming increasingly selective.
With Treasury yields around:
5%
and investors able to earn substantial returns from bonds, companies need a powerful reason to attract capital.
On October 1, the winners had one:
AI demand
better-than-expected earnings
legal protection
or
contracted growth.
The losers had equally specific problems.
That may be the defining feature of the next phase of the market.
The major indexes can appear almost motionless while individual companies gain or lose billions of dollars in a single afternoon — and as AI, interest rates and corporate restructuring collide, picking the right catalyst may matter far more than simply picking the right index.
